# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The biotechnology company said deramiocel increased cardiac function based on several different measures.
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patient...
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for ...
-SEC Filing
Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA).
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the on...
--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP...